Rhian Touyz Chair
I am the British Heart Foundation Chair in Cardiovascular Medicine, based in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
I am a clinician-scientist investigating the molecular and cellular mechanisms of hypertension. I am committed to hypertension through clinical and basic research, clinical service, teaching, mentoring and leadership and to establishing international networks for trainees and new investigators in hypertension research.
Sofie Brouwers Member
As a clinician-scientist, I conduct therapeutic research along with my clinical work. My basic research activities focus on the pathophysiology of hypertension, with special interest for the role of the renin angiotensin system and the central nervous system in the long-term regulation of blood pressure.
Louise Burrell Member
My research interests include the pathophysiology of hypertension, with particular regard to the renin angiotensin system; diabetic heart disease and the role of echocardiography; and novel biomarkers in coronary artery disease.
Fadi Charchar Member
My research interests focus on genomics of cardiovascular disease in humans and animal models. I have a special interest in the contribution of the Y chromosome and microRNA to hypertension.
Alta Schutte Member
As the Research Chair in Chronic Diseases in South Africa, my research spans clinical and epidemiological population studies focusing on the development of hypertension in African communities. By using longitudinal transdisciplinary research programmes I aim to identify novel markers and/or bio-signatures as early predictors of vascular dysfunction in an attempt to contribute to the prevention of hypertension.
Ulrike Steckelings Member
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Latest tweets from ISH Follow us
The ISH is positively committed to opposing discrimination against people on the grounds of gender, race, colour, nationality, religion, marital status, sexual orientation, class, age, disability, having dependants, HIV status or perceived lifestyle.